Clare McGrane

Biomatics Capital raises $300M fund, hires Gates Foundation global health director Mike Poole to lead neurology investments

Biomatics Capital raised a $300 million second fund to invest in 15–20 healthcare and life-sciences startups focused on innovations at the intersection of healthcare and technology, and added two partners — Dr. Mike Poole from the Bill & Melinda Gates Foundation to lead neurology-focused, data- and genomics-enabled investments, and biotech investor Errik Anderson.

SEngine Precision Medicine raises $3M (round now $8.2M), adds Nobel laureate Lee Hartwell and investor Elliott Burkland to board

SEngine Precision Medicine raised $3 million, bringing its current round to $8.2 million, and appointed former Fred Hutch president and Nobel laureate Dr. Lee Hartwell to its board; new investor Elliott Burkland of Bangarang Group will also join the board. The company uses its PARIS test to grow patients’ tumor cells as organoids and analyze drug combinations to personalize cancer treatment.

Stealth biotech Receptor Life Sciences raises $7.5M to develop inhalable plant-extract pharmaceuticals targeting pain, CNS and chemo side effects

Receptor Life Sciences, a stealthy Seattle-area biotech founded in 2015, raised just over $7.5 million and is developing inhalable pharmaceutical preparations derived from plant extracts to treat conditions including pain, CNS and metabolic and gastrointestinal disorders, and chemotherapy side effects. The company declined to name investors or disclose the specific plant, lists minimal public personnel, and had a USPTO appeal to trademark its name rejected.

OncoResponse raises $40M Series B to advance five antibody-based cancer immunotherapies into preclinical and clinical trials

OncoResponse raised $40 million in a Series B to push five antibody-based cancer immunotherapy candidates into preclinical and clinical studies, bringing total funding to nearly $70 million since its 2015 launch. The company mines antibodies from cancer patients who had exceptional responses to immunotherapy to develop treatments that modulate tumor‑microenvironment immunosuppression.

DreamBox Learning raises $130M from The Rise Fund; Arne Duncan joins board as investor takes majority stake

DreamBox Learning raised $130 million from The Rise Fund, which will take a majority stake and add former U.S. Education Secretary Arne Duncan to DreamBox’s board; the company will use the capital to scale operations and expand its ML-driven K–8 math platform into more schools. DreamBox, used by nearly 3 million students and recently launched in Spanish in Mexico, emphasizes personalized, adaptive learning and aligned social-impact goals with its new investor.

Seattle Children’s spin-out MDMetrix raises $758,000 seed to build automated A/B testing for clinicians

MDMetrix, a Seattle Children’s spin-out cofounded by anesthesiologist Dan Low and engineer Matthew Goos, raised just over $758,000 in seed funding to build an automated A/B testing platform that lets doctors compare real-world data on drugs, procedures, and devices. The company incubated inside Seattle Children’s, has four full-time employees (not counting Low, who takes no salary), and Low plans to hand off CEO duties once the startup is established.

Proniras launches in Seattle to develop Eli Lilly’s tezampanel, wins $89.5M BARDA contract

Proniras Corporation launched in Seattle to develop tezampanel, a seizure drug originally created by Eli Lilly, and secured an $89.5 million BARDA contract contingent on development milestones. The company also received undisclosed launch funding from several investors, will be led by co-founder and CSO Chris Toombs, and plans to explore tezampanel as both a seizure therapy and a nerve-agent antidote.

Online